Andere Sprachen AdAlta Limited

Aktien

Markt geschlossen - Australian S.E. Andere Börsenplätze 08:10:47 10.05.2024			% 5 Tage	% 1. Jan.
0,023 ^AUD	0,00 %		-14,81 %	-4,17 %

08.04.	AdAlta erforscht Krebsimmuntherapien Joint Venture für westlichen Markt	MT
26.02.	AdAlta Limited meldet Gewinnergebnisse für das am 31. Dezember 2023 endende Halbjahr	CI

AdAlta Secures Up to AU$3.7 Million for MOU, i-body Programs	29.04.
AdAlta Explores Cancer Immunotherapies Joint Venture for Western Market	08.04.
AdAlta delivers positive Phase I Extension Study results for AD-214	08.03.
AdAlta Limited Reports Earnings Results for the Half Year Ended December 31, 2023	26.02.
AdAlta-La Trobe University Collab Discovers New i-Bodies for Malaria Treatment; Shares Climb 4%	19.12.
Adalta Posts Upbeat Results from Phase I Trial of Fibrotic Disease Drug	22.11.
AdAlta closes oversubscribed $1.65 million raise	08.11.
AdAlta Raises AU$1.7 Million Via Oversubscribed Placement; Shares Down 9%	07.11.
AdAlta to Seeks AU$1.2 Million from Share Placement	03.11.
AdAlta making material progress on partnering talks	23.10.23
AdAlta Receives AU$2.4 Million R&D Tax Rebate	18.10.23
AdAlta says new AD-214 dosing models enhance partnering potential	26.09.23
AdAlta completes enrolment for AD-214 fibrosis safety trial	21.09.23
Adalta Completes Enrollment for Phase 1 Study on Fibrotic Disease Medication; Shares Fall 9%	20.09.23
AdAlta Limited Reports Earnings Results for the Full Year Ended June 30, 2023	25.08.23
AdAlta to Present at August 24th Virtual Investor Summit	16.08.23
AdAlta back in the clinic with AD-214	07.08.23
Adalta Carries Out First Dosing in Phase One Extension Study of Fibrotic Disease Medication; Shares Jump 4%	04.08.23
AdAlta eyes AD-214 Phase I extension study	18.07.23
AdAlta Raises AU$1.9 Million Via Oversubscribed Shortfall Facility	13.07.23

Keine Ergebnisse zu dieser Suche